Immunoglobulin A (De Novo) Vasculitis after mRNA Moderna COVID-19 Vaccination: A Case Report
Infectious Diseases in Clinical Practice
; 30(5) (no pagination), 2022.
Article
in English
| EMBASE | ID: covidwho-2312226
ABSTRACT
Concurrent with the administration of vaccines for the novel coronavirus (COVID-19), there have been many reported adverse effects, and many of them anticipated as with any vaccine administration. This case report, however, focuses on a patient who, shortly after receiving the first dose of the Moderna COVID-19 vaccine, developed a pruritic maculopapular rash with typical distribution and clinical characteristics, along with high levels of immunoglobulin A (IgA), consistent with IgA vasculitis, formerly known as Henoch-Schonlein purpura. Although there are reported cases of IgA vasculitis after different vaccine administrations, to our knowledge, there are no reports of development of this condition after COVID-19 vaccination. The patient did not have any other triggering events or factors that could be attributed to the development of this pathology. This case describes the development of IgA vasculitis after the COVID-19 vaccination. Copyright © Wolters Kluwer Health, Inc. All rights reserved.
covid-19; IgA vasculitis; vaccination; adult; anaphylactoid purpura; article; case report; clinical article; clinical feature; coronavirus disease 2019; drug therapy; female; gene expression; human; immunoglobulin blood level; maculopapular rash; male; protein expression; side effect; vasculitis; elasomeran; endogenous compound; immunoglobulin; immunoglobulin A; messenger RNA
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Case report
Topics:
Vaccines
Language:
English
Journal:
Infectious Diseases in Clinical Practice
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS